Albiglutide significantly reduced the incidence of MACE by 22% compared to placebo (HR 0.78; 95% CI, 0.68–0.90; P<0.0001). The reduction was largely driven by a significant decrease in nonfatal myocardial infarction. Cardiovascular and all-cause mortality were not significantly different between groups. Albiglutide was well tolerated with a safety profile consistent with previous GLP-1 RAs. Here, GLP1R is linked to myocardial infarction.